Drug Trial Radar · NCT07655427
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SRSD107 in Healthy Chinese Subjects
Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Mar 29, 2024
Primary completion
Mar 2, 2025
Study completion Mar 2, 2025
Sponsor
- Lead sponsor
- Sirius Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This was a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneously administered SRSD107 in Chinese healthy subjects. SRSD107 is a synthetic, chemically modified double-stranded siRNA designed to silence hepatic FXI mRNA, thereby modulating coagulation.
Conditions
- Thrombus
Interventions
SRSD107Drug
SRSD107 is a synthetic, chemically modified double-stranded siRNA designed to silence hepatic FXI mRNA, thereby modulating coagulation.
PlaceboDrug
Sodium chloride for subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of adverse events (AEs)Time frame: up to 168 days post last dose
- Proportion of Serious Adverse Events (SAEs)Time frame: up to 168 days post last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.